{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:15:03Z","timestamp":1783955703083,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014489","name":"Johnson & Johnson Pharmaceutical Research and Development LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014489","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.euo.2025.07.002","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:31:41Z","timestamp":1759343501000},"page":"1311-1320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of TITAN"],"prefix":"10.1016","volume":"8","author":[{"given":"Alejo","family":"Rodriguez-Vida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Borque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Lopez-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro Juarez","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Garcillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Lencart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitabha","family":"Bhaumik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneel D.","family":"Mundle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzy Van","family":"Sanden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim N.","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Bjartell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel S.","family":"Merseburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.07.002_b0005","unstructured":"American Cancer Society. Hormone therapy for prostate cancer. https:\/\/www.cancer.org\/cancer\/types\/prostate-cancer\/treating\/hormone-therapy.html."},{"key":"10.1016\/j.euo.2025.07.002_b0010","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.euros.2024.06.006","article-title":"Survival patterns based on first-site-specific visceral metastatic prostate cancer: are outcomes of visceral metastases the same?","volume":"66","author":"Ahmed","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2025.07.002_b0015","series-title":"EAU - EANM - ESTRO - ESUR - ISUP \u2013 SIOG Guidelines on prostate cancer","author":"Cornford","year":"2025"},{"key":"10.1016\/j.euo.2025.07.002_b0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer: report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.07.002_b0025","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.euros.2022.12.002","article-title":"Prostate cancer tumor volume and genomic risk","volume":"48","author":"Ramaswamy","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2025.07.002_b0030","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.07.002_b0035","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.07.002_b0040","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.eururo.2018.02.001","article-title":"Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies","volume":"73","author":"Gravis","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.07.002_b0045","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase, respectively III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.07.002_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113290","article-title":"Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: a subgroup analysis of the randomised clinical TITAN study","volume":"193","author":"Merseburger","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2025.07.002_b0055","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/cas.14722","article-title":"Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients","volume":"112","author":"Shiota","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.euo.2025.07.002_b0060","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2025.07.002_b0065","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","article-title":"Management of patients with advanced prostate cancer: report of the Advanced Prostate Cancer Consensus Conference 2019","volume":"77","author":"Gillessen","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.07.002_b0070","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euo.2025.07.002_b0075","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/pros.23958","article-title":"How many bone metastases may be defined as high-volume metastatic prostate cancer in Asians: a retrospective multicenter cohort study","volume":"80","author":"Yamada","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2025.07.002_b0080","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","article-title":"Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer","volume":"34","author":"Halabi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.07.002_b0085","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamaoncol.2020.7857","article-title":"Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial","volume":"7","author":"Ali","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2025.07.002_b0090","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41391-020-0255-x","article-title":"The prognostic value of pain in castration-sensitive prostate cancer","volume":"23","author":"Iacovelli","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2025.07.002_b0095","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.07.002_b0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.07.002_b0105","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.07.002_b0110","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.07.002_b0115","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.07.002_b0120","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.07.002_b0125","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.07.002_b0130","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1200\/JCO.23.00155","article-title":"Initial management of noncastrate advanced, recurrent, or metastatic prostate cancer: ASCO guideline update","volume":"41","author":"Virgo","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.07.002_b0135","doi-asserted-by":"crossref","DOI":"10.1097\/JU9.0000000000000137","article-title":"Expert perspectives on controversies in castration-sensitive prostate cancer management: narrative review and report of the first US Prostate Cancer Conference Part 1","volume":"2","author":"Crawford","year":"2024","journal-title":"JU Open Plus"},{"key":"10.1016\/j.euo.2025.07.002_b0140","doi-asserted-by":"crossref","unstructured":"Fizazi K, Gillessen S, ESMO Guidelines Committee. Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents. Ann Oncol 2023;34:557\u201363.","DOI":"10.1016\/j.annonc.2023.02.015"},{"key":"10.1016\/j.euo.2025.07.002_b0145","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.07.002_b0150","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.07.002_b0155","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2022.40.6_suppl.089","article-title":"The effect of prior docetaxel (DOC) treatment on efficacy and safety of apalutamide (APA) plus androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) from TITAN","volume":"40","author":"Chi","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.07.002_b0160","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.annonc.2023.02.009","article-title":"Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer","volume":"34","author":"Chowdhury","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.07.002_b0165","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S2666-1683(24)01251-5","article-title":"P124 Apalutamide for metastatic castration-sensitive prostate cancer: outcomes in patients with more than 10 bone metastases from the titan final analysis","volume":"70","author":"Rodriguez-Vida","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2025.07.002_b0170","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","article-title":"First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:35:01Z","timestamp":1766511301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125001944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2588931125001944"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.07.002","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apalutamide in Patients with High Burden of Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of TITAN","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}